Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
| Stage | Treatment Options |
|---|---|
| Stage I nasopharyngeal carcinoma | Radiation therapy |
| Stages II, III, and IV nasopharyngeal carcinoma | Radiation therapy |
| Concurrent chemoradiation | |
| Neoadjuvant chemotherapy and concurrent chemoradiation | |
| Concurrent chemoradiation and adjuvant chemotherapy | |
| Neoadjuvant chemotherapy followed by radiation therapy alone | |
| Surgery | |
| Chemotherapy | |
| Metastatic and recurrent nasopharyngeal carcinoma | Radiation therapy |
| Surgery (for highly selected patients) | |
| Chemotherapy/immunotherapy |
Sources: Radiation therapy · Radiation therapy · Concurrent chemoradiation · Neoadjuvant chemotherapy and concurrent chemoradiation · Concurrent chemoradiation and adjuvant chemotherapy · Neoadjuvant chemotherapy followed by radiation therapy alone · Surgery · Chemotherapy · Radiation therapy · Surgery · Chemotherapy/immunotherapy
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[1,2] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[1-3] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[4-6] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[7] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[8]
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I nasopharyngeal carcinoma include:
Radiation therapy.
Sources: Radiation therapy
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
High-dose radiation therapy with chemotherapy is the initial treatment of nasopharyngeal carcinoma.[1] High-dose radiation therapy is given to the primary tumor site and prophylactic radiation therapy is given to the bilateral regional lymph nodes in the neck.[2] Radiation therapy dose and field margins are individually tailored to the location and size of the primary tumor and lymph nodes.[3-6]
Most tumors are exclusively treated with external-beam radiation therapy. For some patients, radiation therapy may be boosted with intracavitary or interstitial implants, or by the use of stereotactic radiosurgery when clinical expertise is available and the anatomy is suitable.[7-11]
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stages II, III, and IV nonmetastatic nasopharyngeal carcinoma include:
Radiation therapy.
Sources: Radiation therapy
Concurrent chemoradiation.
Sources: Concurrent chemoradiation
Neoadjuvant chemotherapy and concurrent chemoradiation.
Sources: Neoadjuvant chemotherapy and concurrent chemoradiation
Concurrent chemoradiation and adjuvant chemotherapy.
Sources: Concurrent chemoradiation and adjuvant chemotherapy
Neoadjuvant chemotherapy followed by radiation therapy alone. This option is being studied.[1]
Sources: Neoadjuvant chemotherapy followed by radiation therapy alone · 1
Surgery.
Sources: Surgery
Chemotherapy.
Sources: Chemotherapy
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
High-dose radiation therapy with chemotherapy is the initial treatment of nasopharyngeal carcinoma.[2] High-dose radiation therapy is given to the primary tumor site and prophylactic radiation therapy is given to the bilateral regional lymph nodes in the neck.[3] Some studies have reported treatment using altered fractionation radiation therapy.[4,5] Radiation therapy dose and field margins are individually tailored to the location and size of the primary tumor and lymph nodes.[6-9]
Most tumors are exclusively treated with external-beam radiation therapy (EBRT). For some patients, radiation therapy may be boosted with intracavitary or interstitial implants, or by the use of stereotactic radiosurgery when clinical expertise is available and the anatomy is suitable.[10-14]
Evidence (radiation therapy):
A multicenter, noninferiority, phase III trial (NCT02633202) evaluated radiation therapy alone versus chemoradiation therapy for patients with low-risk, stage II, T3, N0, M0 (American Joint Committee on Cancer 7th edition staging) nasopharyngeal carcinoma. The study was performed in endemic China, where almost all cases of nasopharyngeal carcinoma are caused by the Epstein-Barr virus (EBV). In this trial, 341 patients were randomly assigned to receive either intensity-modulated radiation therapy (IMRT) alone (n = 172) or concurrent chemoradiation therapy (IMRT with cisplatin 100 mg/m2 every 3 weeks for three cycles [n = 169]). The primary end point was 3-year failure-free survival (FFS).[15][Level of evidence B1]This trial shows that radiation therapy alone could be used for limited-stage disease if the EBV titers (which are not usually tested in the United States) show fewer than 4,000 copies/mL. Radiation therapy alone was not previously considered a standard of care, but based on these results, patients with lower-volume disease and a low EBV titer may consider radiation therapy alone.
Sources: NCT02633202 · 15 · Level of evidence B1
A multicenter, noninferiority, phase III trial (NCT02633202) evaluated radiation therapy alone versus chemoradiation therapy for patients with low-risk, stage II, T3, N0, M0 (American Joint Committee on Cancer 7th edition staging) nasopharyngeal carcinoma. The study was performed in endemic China, where almost all cases of nasopharyngeal carcinoma are caused by the Epstein-Barr virus (EBV). In this trial, 341 patients were randomly assigned to receive either intensity-modulated radiation therapy (IMRT) alone (n = 172) or concurrent chemoradiation therapy (IMRT with cisplatin 100 mg/m2 every 3 weeks for three cycles [n = 169]). The primary end point was 3-year failure-free survival (FFS).[15][Level of evidence B1]This trial shows that radiation therapy alone could be used for limited-stage disease if the EBV titers (which are not usually tested in the United States) show fewer than 4,000 copies/mL. Radiation therapy alone was not previously considered a standard of care, but based on these results, patients with lower-volume disease and a low EBV titer may consider radiation therapy alone.
The 3-year FFS rate was 90.5% in the IMRT-alone group and 91.9% in the concurrent chemoradiation therapy group (difference, −1.4%; one-sided 95% confidence interval [CI], −7.4% to infinity; P for noninferiority < .001). There were no differences in rates of overall survival (OS), locoregional relapse, or distant metastasis between the two arms.
Patients in the IMRT-alone group experienced significantly lower grades 3 and 4 toxicity, including hematologic and nonhematologic toxicities (nausea, vomiting, anorexia, weight loss, mucositis). The IMRT-alone group had better quality-of-life scores during radiation therapy.
In addition to the trial being conducted in an area where almost all patients with nasopharyngeal carcinoma had cases caused by EBV, all patients had an EBV DNA cut-off of fewer than 4,000 copies/mL to be eligible for entry into the trial. Patients with stage II (T1–2, N1) tumors and nodal disease had to have a nodal size smaller than 3 cm, without extranodal extension, to be eligible for the trial.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Studies and meta-analyses investigating chemoradiation combinations have been reported.[16][Level of evidence C1]; [2,17-30] Overall, these results report increased survival when chemotherapy is added to radiation therapy.[31]
Evidence (neoadjuvant chemotherapy vs. chemoradiation therapy):
Data from phase III randomized trials support induction chemotherapy with gemcitabine plus cisplatin before concurrent chemoradiation therapy.[30,32-34]
A multicenter, randomized, controlled, phase III trial (NCT01872962) compared gemcitabine and cisplatin induction chemotherapy plus concurrent chemoradiation therapy with concurrent chemoradiation therapy alone. At a median follow-up of 42.7 months, the 3-year recurrence-free survival rate was 85.3% for patients in the induction chemotherapy group and 76.5% for patients in the standard therapy group (stratified hazard ratio [HR] recurrence or death, 0.51; 95% CI, 0.34–0.77; P = .001).[30][Level of evidence B1] In a multicenter phase III trial, patients were randomly assigned to receive either concurrent chemoradiation therapy alone (standard therapy, n = 238) or gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiation therapy (n = 242). With a median follow-up of 69.8 months, patients in the induction chemotherapy group had a significantly higher 5-year OS rate (87.9%) than those in the standard therapy group (78.8%) (HR, 0.51; 95% CI, 0.34–0.78; P = .001). The risk of late toxicities was comparable (grade 3 or higher toxicity, 11.3% vs. 11.4%).[32][Level of evidence B1]
Sources: NCT01872962 · 30 · Level of evidence B1 · 32 · Level of evidence B1
Evidence (chemoradiation therapy plus adjuvant chemotherapy):
Chemoradiation therapy followed by adjuvant chemotherapy was used in the INT-0099 trial.[16][Level of evidence C1]
Sources: 16 · Level of evidence C1
Chemoradiation therapy followed by adjuvant chemotherapy was used in the INT-0099 trial.[16][Level of evidence C1]
Patients with parapharyngeal extension were originally staged as T3 in the INT-0099 study and are now considered T2 in the current staging.
The control rate at 3 years was 91.7% in the radiation therapy group (median follow-up period, 34 months) and 100% in the chemoradiation and adjuvant chemotherapy group (median follow-up period, 44 months) (P =.10). The 3-year disease-free survival (DFS) rate was 91.7% in the radiation therapy group and 96.9% in the chemoradiation and adjuvant chemotherapy group (P =.66).
Evidence (combination chemotherapy plus radiation therapy vs. radiation therapy alone):
Three randomized prospective trials compared combination chemotherapy (i.e., cisplatin, epirubicin, and bleomycin or cisplatin plus fluorouracil [5-FU] infusion) plus radiation therapy with radiation therapy alone.[17][Level of evidence A1]; [35,36][Level of evidence B1]
Sources: 17 · Level of evidence A1 · 35 · 36 · Level of evidence B1
Three randomized prospective trials compared combination chemotherapy (i.e., cisplatin, epirubicin, and bleomycin or cisplatin plus fluorouracil [5-FU] infusion) plus radiation therapy with radiation therapy alone.[17][Level of evidence A1]; [35,36][Level of evidence B1]
Although DFS was improved in the chemotherapy group, for both groups, improvement in OS was reported only from the Intergroup trial in which chemotherapy with cisplatin was given concurrently with radiation therapy.[17]
Sources: 17
Evidence (chemoradiation therapy using carboplatin vs. cisplatin):
A study of 1,355 patients compared radiation therapy given concurrently with carboplatin or cisplatin that was administered with a 96-hour infusion of 5-FU monthly for three cycles.[37][Level of evidence A1]
Sources: 37 · Level of evidence A1
A study of 1,355 patients compared radiation therapy given concurrently with carboplatin or cisplatin that was administered with a 96-hour infusion of 5-FU monthly for three cycles.[37][Level of evidence A1]
The 3-year DFS rate was 63.4% for patients in the cisplatin arm and 60.9% for patients in the carboplatin arm (HR, 0.70; 95% CI, 0.50–0.98; P = .961).
OS rates were 77% for patients in the cisplatin arm and 79% for patients in the carboplatin arm (HR, 0.83; 95% CI, 0.63–1.010; P = .988).
Toxicity to kidneys and red blood cell count was greater in patients in the cisplatin group.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Neck dissection may be indicated for patients with persistent or recurrent lymph nodes if the primary tumor site is controlled.[10]
Sources: 10
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for metastatic and recurrent nasopharyngeal carcinoma include:
Radiation therapy.
Sources: Radiation therapy
Surgery (for highly selected patients).
Sources: Surgery
Chemotherapy/immunotherapy.
Sources: Chemotherapy/immunotherapy
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
High-dose radiation therapy with chemotherapy is the initial treatment of patients with nasopharyngeal carcinoma for the primary tumor site and the neck.[1] Selected patients with local recurrence may be retreated with moderate-dose external-beam radiation therapy (EBRT) using intensity-modulated radiation therapy, stereotactic radiation therapy, or intracavitary or interstitial radiation to the site of recurrence.[2-4]; [5][Level of evidence C2]; [6-9][Level of evidence C3] Radiation therapy dose and field margins are individually tailored to the location and size of the primary tumor and lymph nodes.[10-13]
Sources: 1 · 2 · 4 · 5 · Level of evidence C2 · 6 · 9 · Level of evidence C3 · 10 · 13
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
In highly selected patients, surgical resection of locally recurrent lesions may be considered.
Source: Nasopharyngeal Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
If a patient has metastatic disease or local recurrence that is no longer amenable to surgery or radiation therapy, chemotherapy or immunotherapy may be considered.[18-20]
Evidence (chemotherapy/immunotherapy):
The international, multicenter, randomized, double-blind, phase III JUPITOR-02 study (NCT03581786) was conducted in nasopharyngeal carcinoma–endemic regions, including mainland China, Taiwan, and Singapore. The trial randomly assigned 289 patients to receive either toripalimab, a humanized IgG4K monoclonal antibody against human programmed death 1 (PD-1), (240 mg/m2) or placebo in combination with gemcitabine and cisplatin for up to six cycles. Patients also received maintenance therapy with toripalimab or placebo until disease progression, intolerable toxicity, or completion of 2 years of treatment. The primary end point was progression-free survival (PFS) as assessed by a blinded independent central review. Secondary end points included objective response rate, overall survival (OS), PFS as assessed by an investigator, duration of response, and safety. The median survival follow-up was 36 months.[21]
Sources: JUPITOR-02 · 21
The international, multicenter, randomized, double-blind, phase III JUPITOR-02 study (NCT03581786) was conducted in nasopharyngeal carcinoma–endemic regions, including mainland China, Taiwan, and Singapore. The trial randomly assigned 289 patients to receive either toripalimab, a humanized IgG4K monoclonal antibody against human programmed death 1 (PD-1), (240 mg/m2) or placebo in combination with gemcitabine and cisplatin for up to six cycles. Patients also received maintenance therapy with toripalimab or placebo until disease progression, intolerable toxicity, or completion of 2 years of treatment. The primary end point was progression-free survival (PFS) as assessed by a blinded independent central review. Secondary end points included objective response rate, overall survival (OS), PFS as assessed by an investigator, duration of response, and safety. The median survival follow-up was 36 months.[21]
The median OS was not reached in the toripalimab group (95% confidence interval [CI], 38.7 months–not estimable) and was 33.7 months (95% CI, 27.0–44.2) in the placebo group (hazard ratio [HR], 0.63; 95% CI, 0.45–0.89; P = .0083).[21][Level of evidence A1]
Sources: 21 · Level of evidence A1
PFS was significantly longer in the toripalimab arm compared with the placebo arm, with a median PFS of 21.4 months in the toripalimab group versus 8.2 months in the placebo group (HR, 0.52; 95% CI, 0.37–0.73).
Grade 3 or higher immune-related adverse events occurred in 9.6% of patients in the toripalimab group. Treatment discontinuation occurred in 11.6% of patients in the toripalimab group and 4.9% of patients in the placebo group.
A multicenter, randomized, open-label, phase III trial included patients with recurrent or metastatic nasopharyngeal carcinoma recruited from 22 hospitals in China. Patients were randomly assigned in a 1:1 ratio to receive either gemcitabine (1 g/m2 intravenously [IV] on days 1 and 8) and cisplatin (80 mg/m2 IV on day 1), or fluorouracil ([5-FU] 4 g/m2 in continuous IV infusion over 96 h) and cisplatin (80 mg/m2 IV on day 1) once every 3 weeks for a maximum of six cycles.[22] Of the 362 patients, 181 were assigned to the gemcitabine-plus-cisplatin group and 181 to the 5-FU-plus-cisplatin group.
Sources: 22
A multicenter, randomized, open-label, phase III trial included patients with recurrent or metastatic nasopharyngeal carcinoma recruited from 22 hospitals in China. Patients were randomly assigned in a 1:1 ratio to receive either gemcitabine (1 g/m2 intravenously [IV] on days 1 and 8) and cisplatin (80 mg/m2 IV on day 1), or fluorouracil ([5-FU] 4 g/m2 in continuous IV infusion over 96 h) and cisplatin (80 mg/m2 IV on day 1) once every 3 weeks for a maximum of six cycles.[22] Of the 362 patients, 181 were assigned to the gemcitabine-plus-cisplatin group and 181 to the 5-FU-plus-cisplatin group.
The median follow-up time for PFS was 19.4 months (interquartile range [IQR], 12.1–35.6). The median PFS was 7.0 months (range, 4.4–10.9) in the gemcitabine group and 5.6 months (range, 3.0–7.0) in the 5-FU group (HR, 0.55; 95% CI, 0.44–0.68; P < .0001).[22][Level of evidence B1]
Sources: 22 · Level of evidence B1
There were significant differences in the incidences of the following grade 3 or 4 treatment-related adverse events:
A multicenter, randomized, open-label, phase III trial included patients with recurrent or metastatic nasopharyngeal carcinoma recruited from 22 hospitals in China. Patients were randomly assigned in a 1:1 ratio to receive either gemcitabine (1 g/m2 intravenously [IV] on days 1 and 8) and cisplatin (80 mg/m2 IV on day 1), or fluorouracil ([5-FU] 4 g/m2 in continuous IV infusion over 96 h) and cisplatin (80 mg/m2 IV on day 1) once every 3 weeks for a maximum of six cycles.[22] Of the 362 patients, 181 were assigned to the gemcitabine-plus-cisplatin group and 181 to the 5-FU-plus-cisplatin group. › There were significant differences in the incidences of the following grade 3 or 4 treatment-related adverse events:
Leukopenia (52 [29%] in the gemcitabine group vs.15 [9%] in the 5-FU group; P < .0001).
Neutropenia (41 [23%] in the gemcitabine group vs. 23 [13%] in the 5-FU group; P = .0251).
Thrombocytopenia (24 [13%] in the gemcitabine group vs. 3 [2%] in the 5-FU group; P = .0007).
Mucosal inflammation (0 in the gemcitabine group vs. 25 [14%] in the 5-FU group; P < .0001).
A multicenter, randomized, open-label, phase III trial included patients with recurrent or metastatic nasopharyngeal carcinoma recruited from 22 hospitals in China. Patients were randomly assigned in a 1:1 ratio to receive either gemcitabine (1 g/m2 intravenously [IV] on days 1 and 8) and cisplatin (80 mg/m2 IV on day 1), or fluorouracil ([5-FU] 4 g/m2 in continuous IV infusion over 96 h) and cisplatin (80 mg/m2 IV on day 1) once every 3 weeks for a maximum of six cycles.[22] Of the 362 patients, 181 were assigned to the gemcitabine-plus-cisplatin group and 181 to the 5-FU-plus-cisplatin group.
Serious treatment-related adverse events occurred in seven patients (4%) in the gemcitabine group and ten patients (6%) in the 5-FU group.
Six patients (3%) in the gemcitabine group and 14 patients (8%) in the 5-FU group discontinued treatment because of drug-related adverse events.
No treatment-related deaths occurred in either group.
POLARIS-02 (NCT02915432) was a phase II, open-label, multicenter, single-arm trial in China that enrolled 190 patients with recurrent or metastatic nasopharyngeal carcinoma. Patients received toripalimab (3 mg/kg) once every 2 weeks until disease progression or unacceptable toxicity. Patients had received prior platinum-based chemotherapy or had disease progression within 6 months of completion of platinum-based chemotherapy given as neoadjuvant, adjuvant, or definitive chemoradiation therapy for locally advanced disease. The primary end point was objective response rate. The secondary end points included safety, duration of response, PFS, and OS.[23]
Sources: POLARIS-02 · 23
POLARIS-02 (NCT02915432) was a phase II, open-label, multicenter, single-arm trial in China that enrolled 190 patients with recurrent or metastatic nasopharyngeal carcinoma. Patients received toripalimab (3 mg/kg) once every 2 weeks until disease progression or unacceptable toxicity. Patients had received prior platinum-based chemotherapy or had disease progression within 6 months of completion of platinum-based chemotherapy given as neoadjuvant, adjuvant, or definitive chemoradiation therapy for locally advanced disease. The primary end point was objective response rate. The secondary end points included safety, duration of response, PFS, and OS.[23]
The objective response rate was 20.5%, with a median duration of response of 12.8 months, a median PFS of 1.9 months, and a median OS of 17.4 months.[23][Level of evidence C3]
Sources: 23 · Level of evidence C3
The U.S. Food and Drug Administration has approved toripalimab with cisplatin and gemcitabine as first-line treatment for patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma. It is also approved as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression during or after platinum-containing therapy.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on:
Sources: prognosis
the size of the tumor
the stage of the cancer, including whether cancer has spread to one or more lymph nodes in the neck
Sources: stage · lymph nodes
whether there are high levels of EBV antibodies and EBV-DNA markers in the blood before and after treatment
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Recurrent nasopharyngeal cancer is cancer that has come back after it has been treated. If nasopharyngeal cancer comes back, it may come back in the nasopharynx, lymph nodes, or other parts of the body, such as the lungs, bone, or liver. Tests will help determine where in the body the cancer has returned. The type of treatment that you have for recurrent nasopharyngeal cancer will depend on where it has come back.
Learn more in Recurrent Cancer: When Cancer Comes Back.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
There are different types of treatment for people with nasopharyngeal cancer.
People with nasopharyngeal cancer should have their treatment planned by a team of doctors with expertise in treating head and neck cancer.
The following types of treatment are used:
The following types of treatment are used:
Radiation therapy
Chemotherapy
Surgery
Immunotherapy
Treatment for nasopharyngeal cancer may cause side effects.
New types of treatment are being tested in clinical trials.
Follow-up care may be needed.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Different types of treatments are available for nasopharyngeal cancer. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.
Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. Learn more at Questions to Ask Your Doctor About Your Treatment.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
An oncologist, a doctor who specializes in treating people with cancer, oversees treatment for nasopharyngeal cancer. Because the nasopharynx helps in breathing, eating, and talking, you may need help adjusting to the side effects of the cancer and its treatment. The oncologist may refer you to other health care providers who are experts in treating head and neck cancer and also specialize in other areas of medicine. Other specialists may include:
Sources: side effects · head and neck cancer
head and neck surgeon
radiation oncologist
Sources: radiation oncologist
plastic surgeon
Sources: plastic surgeon
dentist
Sources: dentist
dietitian
Sources: dietitian
psychologist
Sources: psychologist
rehabilitation specialist
Sources: rehabilitation specialist
speech therapist
Sources: speech therapist
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing by damaging their DNA. The way radiation therapy is given depends on the type and stage of the cancer. External and internal radiation therapy are used to treat nasopharyngeal cancer.
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These include:External radiation therapy to the thyroid or the pituitary gland may change the way the thyroid gland works. A blood test to check the thyroid hormone level in the blood is done before and after therapy to make sure the thyroid gland is working properly. It is also important that a dentist check your teeth, gums, and mouth, and fix any existing problems before radiation therapy begins.
Sources: External radiation therapy · thyroid · pituitary gland · blood test · thyroid hormone
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These include:External radiation therapy to the thyroid or the pituitary gland may change the way the thyroid gland works. A blood test to check the thyroid hormone level in the blood is done before and after therapy to make sure the thyroid gland is working properly. It is also important that a dentist check your teeth, gums, and mouth, and fix any existing problems before radiation therapy begins.
Intensity-modulated radiation therapy (IMRT): IMRT is a type of 3-dimensional (3-D) radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles. Compared to standard radiation therapy, intensity-modulated radiation therapy may be less likely to cause dry mouth. You will likely have treatment once a day, Monday through Friday, for about 6 to 7 weeks.
Stereotactic radiation therapy: Stereotactic radiation therapy also uses a computer to make detailed images of the tumor. Thin beams of radiation are aimed at the tumor from different angles. High-dose radiation is given in one to five sessions spread over several days. This procedure is also called stereotactic external-beam radiation and stereotaxic radiation therapy.
Sources: Stereotactic radiation therapy
Internal radiation therapy (also called brachytherapy) uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. In some cases, it may be used with external radiation therapy to deliver an extra dose of radiation directly to the tumor. Learn more about Brachytherapy to Treat Cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters · Brachytherapy to Treat Cancer
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemotherapy for nasopharyngeal cancer is usually systemic, meaning it is taken by mouth or injected into a vein or muscle. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body.
Sources: Chemotherapy
Chemotherapy drugs used to treat nasopharyngeal cancer include:
carboplatin
Sources: carboplatin
cisplatin
Sources: cisplatin
docetaxel
Sources: docetaxel
fluorouracil
Sources: fluorouracil
gemcitabine
Sources: gemcitabine
Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.
Chemotherapy may be combined with other types of treatment, such as radiation therapy.
To learn more about how chemotherapy works, how it is given, common side effects, and more, visit Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Surgery to remove the tumor is sometimes used for nasopharyngeal cancer that does not respond to radiation therapy. If cancer has spread to the lymph nodes, the doctor may remove lymph nodes and other tissues in the neck.
Sources: respond · lymph nodes
Learn more about Surgery to Treat Cancer.
Sources: Surgery to Treat Cancer
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: Immunotherapy · immune system
PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Toripalimab is a type of PD-1 inhibitor used to treat metastatic or recurrent nasopharyngeal cancer.
Sources: PD-1 · PD-L1 · therapy · protein · T cells · immune responses · Toripalimab · metastatic · recurrent
Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of nasopharyngeal cancer treatment may include:
Sources: late effects
chronic dry mouth
dental and oral complications
Sources: complications
hearing loss
vision loss
difficulty swallowing
lockjaw
problems with the thyroid and pituitary gland
damage to nerves in the brain
changes in mood, feelings, thinking, learning, or memory
Some late effects may be treated or controlled. It is important to talk with your doctor about possible late effects caused by some treatments.
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
After treatment is complete, it is important to have head and neck exams to look for signs that the cancer has come back.
Sources: signs
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stage I nasopharyngeal cancer is usually radiation therapy to the tumor and lymph nodes in the neck.
Sources: stage I nasopharyngeal cancer · radiation therapy · lymph nodes
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stage II, III, and IVA (nonmetastatic) nasopharyngeal cancer may include:
radiation therapy to the tumor and lymph nodes in the neck
Sources: radiation therapy · lymph nodes
chemotherapy given with radiation therapy, followed by more chemotherapy
Sources: chemotherapy
chemotherapy followed by more chemotherapy given with radiation therapy
chemotherapy followed by radiation therapy (under study)
surgery to remove lymph nodes if they still contain cancer cells after initial treatment
chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stage IVB (metastatic) or recurrent nasopharyngeal cancer may include:
Sources: stage IVB · metastatic · recurrent
intensity-modulated radiation therapy, stereotactic radiation therapy, or internal radiation therapy
Sources: intensity-modulated radiation therapy · stereotactic radiation therapy · internal radiation therapy
surgery
chemotherapy, immunotherapy (toripalimab) given alone, or immunotherapy given with chemotherapy
Sources: chemotherapy · immunotherapy · toripalimab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
ClinicalTrials.gov recordNasopharyngeal Carcinoma
ClinicalTrials.gov recordNasopharyngeal Carcinoma
ClinicalTrials.gov recordGastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov recordRecurrent or Metastatic NPC
ClinicalTrials.gov recordNasopharyngeal Carcinoma
ClinicalTrials.gov recordNasopharyngeal Carcinoma
ClinicalTrials.gov record1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or...
Nasopharyngeal Carcinoma
1.1 First-line Treatment of Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma Penpulimab-kcqx, in combination with either cisplatin or carboplatin and gemcitabine, is indicated for the first-line treatment of adults with...
1.2 Recurrent Metastatic Non-Keratinizing Nasopharyngeal Carcinoma Penpulimab-kcqx, as a single agent, is indicated for the treatment of adults with metastatic non-keratinizing NPC and disease progression on or after platinum-based...
Treatment of Metastatic and Recurrent Nasopharyngeal Carcinoma
Treatment of Stage I Nasopharyngeal Carcinoma
Treatment of Stage II, III, and IVA Nasopharyngeal Cancer
Treatment of Stage IVB and Recurrent Nasopharyngeal Cancer
LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma...
DailyMed labelPenpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic...
DailyMed label